Tuesday, May 29, 2018

Best Undervalued Stocks To Own For 2018

tags:NKTR,LXRX,CYBR,SANW,SIGI,

Chipmaker QUALCOMM, Inc. (NASDAQ:QCOM) has been on a wild ride over the past several months. The shares were in a down-trend for most of 2017 until Broadcom Inc (NASDAQ:AVGO) acquisition rumors emerged in October, sending QCOM stock from $50 to $70 in a hurry.

But then U.S. President Donald Trump essentially blocked AVGO’s acquisition attempts. Merger talks went cold. Qualcomm stock dropped. The decline continues, due to a confluence of headwinds, ranging from Chinese regulation to costly lawsuits to weak smartphone demand.

Now, QCOM stock is back at that $50 level of October 2017.

Time to buy? Getting close, but not yet. The fundamentals imply this stock isn’t undervalued yet, while the sentiment remains largely negative. Thus, the best move seems like to wait for the dust to settle.

Let’s tak a deeper look.

QCOM Has Been Absorbed In Wildness

The only way to describe what QCOM has been through over the past several months is simply “wild.”

Best Undervalued Stocks To Own For 2018: Nektar Therapeutics(NKTR)

Advisors' Opinion:
  • [By Stephan Byrd]

    TRADEMARK VIOLATION NOTICE: “Nektar Therapeutics (NKTR) Trading Down 7%” was originally reported by Ticker Report and is the property of of Ticker Report. If you are reading this piece of content on another site, it was stolen and republished in violation of US & international trademark and copyright law. The original version of this piece of content can be viewed at https://www.tickerreport.com/banking-finance/3362849/nektar-therapeutics-nktr-trading-down-7.html.

  • [By Dan Caplinger]

    Friday was a relatively quiet day on Wall Street, with a split among the most widely followed market benchmarks that sent some up and others down. Slight downticks in oil prices and bond yields marked minor reversals from upward trends earlier in the week, but investors are still watching both energy and bonds closely to see what long-term impact they might have on the stock market. Most attention centered on individual companies, some of which reported good news that sent their shares higher. Dell Technologies (NYSE:DVMT), Nektar Therapeutics (NASDAQ:NKTR), and Westport Fuel Systems (NASDAQ:WPRT) were among the best performers on the day. Here's why they did so well.

  • [By Max Byerly]

    HC Wainwright set a $125.00 target price on Nektar Therapeutics (NASDAQ:NKTR) in a report published on Sunday morning. The brokerage currently has a buy rating on the biopharmaceutical company’s stock.

  • [By Maxx Chatsko]

    Shares of biopharma Nektar Therapeutics (NASDAQ:NKTR) dropped over 11% today after the company released an abstract to be presented at the American Society of Clinical Oncology annual meeting next month that contained a disappointing update for an ongoing clinical trial.

  • [By Cory Renauer]

    Even though it's been a rough few years for many of the industry's larger players, some smaller upstarts have produced stunning gains lately. Shares of�Nektar Therapeutics (NASDAQ:NKTR), BeiGene Ltd. (NASDAQ:BGNE), and AveXis Inc. (NASDAQ:AVXS) have risen at least 500% in less than three years.�

Best Undervalued Stocks To Own For 2018: Lexicon Pharmaceuticals, Inc.(LXRX)

Advisors' Opinion:
  • [By Shane Hupp]

    Lexicon Pharmaceuticals (NASDAQ:LXRX) – Analysts at Wedbush issued their Q1 2019 earnings per share (EPS) estimates for Lexicon Pharmaceuticals in a note issued to investors on Monday, May 7th. Wedbush analyst L. Moussatos expects that the biopharmaceutical company will earn ($0.28) per share for the quarter. Wedbush currently has a “Outperform” rating and a $40.00 target price on the stock. Wedbush also issued estimates for Lexicon Pharmaceuticals’ Q2 2019 earnings at ($0.25) EPS, Q3 2019 earnings at ($0.13) EPS, Q4 2019 earnings at ($0.06) EPS, FY2020 earnings at $0.53 EPS, FY2021 earnings at $2.22 EPS and FY2022 earnings at $3.81 EPS.

  • [By Keith Speights]

    Dividend Yield

    Abbott Laboratories (NYSE:ABT) Drugs $109 billion 19.37 1.88% AstraZeneca (NYSE: AZN) Drugs $93 billion 19.70 3.97% Becton Dickinson and Co. (NYSE: BDX) Medical supplies $60 billion 17.74 1.29% DexCom (NASDAQ: DXCM) Medical devices $8 billion N/A N/A Eli Lilly and Co. (NYSE: LLY) Drugs $85 billion 14.91 2.77% Insulet (NASDAQ: PODD) Medical devices $5 billion 273.03 N/A Johnson & Johnson (NYSE: JNJ) Drugs, medical devices $325 billion 14.16 2.57% Lexicon Pharmaceuticals (NASDAQ:LXRX) Drugs $1 billion N/A N/A MannKind (NASDAQ: MNKD) Drugs $270 million N/A N/A Medtronic (NYSE: MDT) Medical devices $117 billion 15.36 2.14% Merck & Co. (NYSE: MRK) Drugs $159 billion 12.99 3.22% Novo Nordisk (NYSE:NVO) Drugs $116 billion 18.29 2.61% Pfizer (NYSE: PFE) Drugs $209 billion 11.62 3.82% Regeneron Pharmaceuticals (NASDAQ: REGN) Drugs $32 billion 13.95 N/A Sanofi (NYSE: SNY) Drugs $95 billion 10.75 4.64% Senseonics Holdings (NYSEMKT: SENS) Medical devices $447 million N/A N/A Tandem Diabetes Care (NASDAQ: TNDM) Medical devices $711 million N/A N/A

    Data source: Yahoo! Finance. P/E = price-to-earnings ratio; N/A = not applicable. Data as of May 25, 2018.

  • [By Shane Hupp]

    Get a free copy of the Zacks research report on Lexicon Pharmaceuticals (LXRX)

    For more information about research offerings from Zacks Investment Research, visit Zacks.com

  • [By Max Byerly]

    Get a free copy of the Zacks research report on Lexicon Pharmaceuticals (LXRX)

    For more information about research offerings from Zacks Investment Research, visit Zacks.com

Best Undervalued Stocks To Own For 2018: CyberArk Software Ltd.(CYBR)

Advisors' Opinion:
  • [By Chris Lange]

    The short interest at CyberArk Software Ltd. (NASDAQ: CYBR) decreased to 697,700 shares from the previous level of 887,900. Shares were trading at $60.24, within a 52-week range of $39.34 to $60.59.

  • [By Chris Lange]

    The short interest at CyberArk Software Ltd. (NASDAQ: CYBR) increased to 1.10 million shares from the previous level of 861,800. Shares were trading at $53.34, within a 52-week range of $39.34 to $55.63.

  • [By Joe Tenebruso]

    Nearly 90%�of security professionals believe that an enterprise's IT infrastructure is not fully protected unless its privileged accounts are secured, according to a survey by CyberArk Software Ltd.�(NASDAQ:CYBR). This global demand for cybersecurity solutions that safeguard an organization's most sensitive data is helping to fuel CyberArk's growth, as evidenced by its strong first-quarter�results.

  • [By Logan Wallace]

    Get a free copy of the Zacks research report on CyberArk (CYBR)

    For more information about research offerings from Zacks Investment Research, visit Zacks.com

Best Undervalued Stocks To Own For 2018: S&W Seed Company(SANW)

Advisors' Opinion:
  • [By Ethan Ryder]

    S&w Seed (NASDAQ:SANW) – Equities researchers at B. Riley decreased their Q3 2019 earnings per share (EPS) estimates for S&w Seed in a research note issued to investors on Thursday, May 10th. B. Riley analyst S. Sherbetchyan now anticipates that the company will post earnings of $0.00 per share for the quarter, down from their previous forecast of $0.01. B. Riley has a “Buy” rating and a $5.50 price objective on the stock.

  • [By Logan Wallace]

    Get a free copy of the Zacks research report on S&w Seed (SANW)

    For more information about research offerings from Zacks Investment Research, visit Zacks.com

Best Undervalued Stocks To Own For 2018: Selective Insurance Group, Inc.(SIGI)

Advisors' Opinion:
  • [By Shane Hupp]

    BidaskClub downgraded shares of Selective Insurance (NASDAQ:SIGI) from a hold rating to a sell rating in a report published on Monday.

    A number of other equities research analysts have also issued reports on SIGI. ValuEngine upgraded shares of Selective Insurance from a hold rating to a buy rating in a report on Friday, February 2nd. Keefe, Bruyette & Woods set a $62.00 price target on shares of Selective Insurance and gave the stock a hold rating in a research note on Monday, February 5th. Zacks Investment Research downgraded shares of Selective Insurance from a buy rating to a hold rating in a report on Wednesday, March 14th. Sandler O’Neill reaffirmed a hold rating and set a $61.00 price objective on shares of Selective Insurance in a report on Friday, April 6th. Finally, Boenning Scattergood reaffirmed a hold rating on shares of Selective Insurance in a report on Thursday, May 3rd. Two investment analysts have rated the stock with a sell rating and five have given a hold rating to the stock. The stock currently has a consensus rating of Hold and an average target price of $62.50.

  • [By Shane Hupp]

    Selective Insurance (NASDAQ:SIGI) – Boenning Scattergood decreased their Q2 2018 earnings per share estimates for shares of Selective Insurance in a research note issued to investors on Thursday, May 3rd. Boenning Scattergood analyst R. Farnam now expects that the insurance provider will earn $0.83 per share for the quarter, down from their prior estimate of $0.96. Boenning Scattergood has a “Hold” rating on the stock. Boenning Scattergood also issued estimates for Selective Insurance’s Q4 2018 earnings at $1.04 EPS, Q1 2019 earnings at $0.88 EPS, Q2 2019 earnings at $0.85 EPS, Q3 2019 earnings at $0.98 EPS and Q4 2019 earnings at $1.05 EPS.

Monday, May 28, 2018

Here��s the Maximum Social Security You Can Get If You Claim at 62

Social Security accounts for more than half of the retirement income for 50% of married couples, so making sure that you get the most money possible from the program is important to achieving financial security in your golden years. The most common age to start receiving Social Security benefits is 62, the earliest age possible, but if you want to collect 100% of the benefits you're owed, you'll have to wait until�full retirement age�(FRA) to claim them. If you file early, Social Security will penalize you with smaller checks.

How much is the maximum you can get in Social Security if you claim at age 62? The amount may disappoint you.

A big penalty

Your monthly full retirement-age Social Security benefit is determined by a complex formula that averages your highest 35 years of inflation-adjusted income and then reduces that average at specific income thresholds called bend points.

A man sitting cross-legged on the floor in a yoga pose as U.S. Dollar bills fall down around him.

IMAGE SOURCE: GETTY IMAGES.

Full retirement age depends on your birth year.�If you were born between 1943 and 1954, your FRA is 66, and if you were born after 1955, it ranges between age 66 and 2 months to age 67. If you retire at that age, you'll get 100% of the amount you're owed in Social Security benefits, but if you claim earlier than that, the amount you get will be significantly less.

The exact amount in benefits you get when you claim at age 62 depends on how many months prior to FRA you begin receiving your benefit.�Specifically, your benefit is reduced by 5/9 of 1% for each month you claim early, up to 36 months. If you claim more than 36 months early, your benefit is reduced by an additional�5/12 of 1% per month.

For instance, if your FRA is 67 and you claim Social Security at age 62, you'd be claiming 60 months early. Using the percentages mentioned above, your payment at age 62 would be 30% lower than it would be at FRA.�

Claim Early Benefit Reduction Amounts (FRA of 67) Age Reduction
62 30%
63 25%
64 20%
65 13.3%
66 6.7%

DATA: SOCIAL SECURITY ADMINISTRATION. AUTHOR'S TABLE.

The maximum Social Security you can collect at 62

Social Security pays benefits to current Social Security recipients with money that's collected in payroll taxes on current workers. In 2018, those payroll taxes apply to taxable earnings of up to $128,400.

When Social Security calculates your FRA benefit, it won't give you credit for any earnings over the maximum earnings limit, so there's a maximum amount you can get in Social Security benefits, regardless of your income.

In 2018, the maximum amount you can get in benefits if you're at the maximum taxable earnings limit and you claim at age 62 is $2,158.

Maximum Social Security if You Retire in 2018 Age Per Month Per Year
62 $2,158 $25,896
65 $2,589 $31,068
70 $3,698 $44,376

DATA SOURCE: SOCIAL SECURITY. CHART BY AUTHOR.

Get credit for waiting

There are plenty of reasons why it can make sense to claim benefits as soon as you can, but you you can collect significantly more in monthly benefits if you decide to delay Social Security rather than take it at age 62.

If you hold off claiming Social Security, you get rewarded with delayed retirement credits that increase your benefit for every month you wait. If you were born in or after 1943, those credits increase your benefit by 2/3 of 1% for every month beyond FRA that you delay, up to age 70. That translates into an 8% annual increase. For instance, if your FRA is 67 and your monthly full retirement benefit is $1,000, then delaying until age 70 results in a monthly check of�$1,240, or 24% more than you'd receive at age 67.�

The amount you can get in benefits by waiting is illustrated in the following table, which breaks out the increases you can receive by FRA at ages 66, 67, and 70.

Birth Year Full Retirement Age Percentage Paid If Claiming at 66� Percentage Paid If Claiming at 67 Percentage Paid If Claiming at 70�
1943-54 66 100% 108% 132%
1955 66, 2 months 98 8/9% 106 2/3% 130 2/3%
1956 66, 4 months 97 7/9% 105 1/3% 129 1/3%
1957 66, 6 months 96 2/3% 104% 128%
1958 66, 8 months 95 5/9% 102 2/3% 126 2/3%
1959 66, 10 months 94 4/9% 101 1/3% 125 1/3%
1960 and later 67 93 1/3% 100% 124%

Data source: Social Security Administration.

Ultimately, when to claim Social Security is a personal decision that's going to depend on�your health, retirement goals, sources of retirement income, and expenses. However,�if you want to get the maximum amount of money possible from Social Security and you're already at the maximum earnings limit, waiting could make more sense than claiming at age 62.

Sunday, May 27, 2018

Hot Gold Stocks To Buy For 2019

tags:ENVA,CDNS,CTT,SRE,VMO,

DekaBank Deutsche Girozentrale acquired a new stake in shares of Uniqure NV (NASDAQ:QURE) during the first quarter, according to its most recent disclosure with the Securities & Exchange Commission. The fund acquired 12,600 shares of the biotechnology company’s stock, valued at approximately $299,000.

A number of other institutional investors and hedge funds also recently made changes to their positions in QURE. SG Americas Securities LLC purchased a new position in Uniqure during the fourth quarter valued at approximately $119,000. Ellington Management Group LLC purchased a new position in Uniqure during the fourth quarter valued at approximately $237,000. Goldman Sachs Group Inc. purchased a new position in Uniqure during the fourth quarter valued at approximately $373,000. Virtus Fund Advisers LLC purchased a new position in Uniqure during the fourth quarter valued at approximately $389,000. Finally, Two Sigma Advisers LP purchased a new position in Uniqure during the fourth quarter valued at approximately $476,000. 43.83% of the stock is currently owned by hedge funds and other institutional investors.

Hot Gold Stocks To Buy For 2019: Enova International, Inc.(ENVA)

Advisors' Opinion:
  • [By Lisa Levin] Gainers Genprex, Inc. (NASDAQ: GNPX) jumped 46.7 percent to $16.1331. The low-float small-cap clinical stage gene therapy company saw its stock rally nearly 150 percent from Monday through Thursday. Formal news hasn't been announced this week that would support a triple-digit percentage rally (including more than 200 percent at one point on Thursday) but the quiet period following its initial public offering will expire on May 8. Celyad SA (NASDAQ: CYAD) shares gained 24.7 percent to $36.17. Celyad reported the publication of THINK study case report of CYAD-01 Induced Complete Remission in relapsed/refractory AML patient in haematologica. DMC Global Inc. (NASDAQ: BOOM) shares jumped 23.2 percent to $39.00 after the company reported upbeat Q1 results and issued upbeat Q2 guidance. eHealth, Inc. (NASDAQ: EHTH) gained 21.8 percent to $19.58 as the company posted upbeat Q1 results. Enova International, Inc. (NYSE: ENVA) climbed 20.4 percent to $27.20 following Q1 results. SVB Financial Group (NASDAQ: SIVB) shares jumped 18.2 percent to $304.135 following strong quarterly results. Knowles Corporation (NYSE: KN) gained 13.9 percent to $12.70 as the company reported Q1 results. Zymeworks Inc. (NYSE: ZYME) gained 13.8 percent to $17.36. Cocrystal Pharma, Inc. (NASDAQ: COCP) rose 11.8 percent to $2.336 after declining 25.09 percent on Thursday. ImmunoGen, Inc. (NASDAQ: IMGN) shares surged 11.7 percent to $11.75 after the company announced 'successful completion of interim analysis' for FORWARD I Phase 3 mirvetuximab soravtansine trial. Eloxx Pharmaceuticals, Inc. (NASDAQ: ELOX) gained 9.5 percent to $12.70. Expedia Group, Inc. (NASDAQ: EXPE) shares rose 8.5 percent to $115.3801 after the company reported stronger-than-expected earnings for its first quarter on Thursday. Sprint Corporation (NYSE: S) shares rose 8.3 percent to $6.50. The stock moved higher after a Reuters report suggested ongoing merger talks with T-M

Hot Gold Stocks To Buy For 2019: Cadence Design Systems, Inc.(CDNS)

Advisors' Opinion:
  • [By Garrett Baldwin]

    Southwest Airlines Inc. (NYSE: LUV) canceled flights across the country in order to inspect the engines of 40 different airplanes. The inspections come a week after a mid-air engine explosion caused the first U.S. air fatality since 2009. Money Morning Executive Editor Bill Patalon breaks down the aftermath of the accident, and explains what it means for both Southwest and Boeing Co. (NYSE: BA). The price of Bitcoin pushed back toward $9,000 as the post-tax season breakout continues for the cryptocurrency markets. The total value of the global cryptocurrency market topped $400 billion this morning, a significant recovery from the massive downturn that occurred in the first quarter. As we explained on Saturday, now may be the best time to buy Bitcoin since July 2013. That month was when Money Morning�Defense and Tech Specialist Michael A. Robinson went on live television with a bold prediction for�Bitcoin (BTC), which would be followed by 25,351% gains at the peak of the cryptocurrency's run. Find out where Bitcoin is heading next, right here. Three Stocks to Watch Today: GOOGL, LUV, HAS Alphabet Inc. (Nasdaq: GOOGL) leads another busy day of earnings reports on Monday. Wall Street anticipates that the online media giant will report earnings per share (EPS) of $9.21 on top of $24.29 billion in revenue. Hasbro Inc. (NYSE: HAS) slumped more than 7.6% in pre-market hours after the company reported earnings. The toymaker reported adjusted EPS of $0.10, well short of the $0.33 expected on Wall Street. The firm also reported weaker-than-expected revenue for the quarter. The firm named Toys 'R Us as a central reason for poor showing – the company recently liquidated its stores, impacting Hasbro Inc.'s (Nasdaq: HAS) bottom lines. Look for earnings reports from Halliburton Co.�(NYSE: HAL), Alaska Air Group Inc.�(NYSE: ALK), Whirlpool Corp. (NYSE: WHR), TD Ameritrade Holding Corp. (Nasdaq: AMTD), Kimberley-Clark Corp. (NYSE: KMB), Cadence Design Syst
  • [By Lisa Levin] Gainers Sanmina Corp (NASDAQ: SANM) shares rose 15.2 percent to $31.90 in pre-market trading as the company reported stronger-than-expected earnings for its second quarter on Monday. Cadence Design Systems, Inc. (NASDAQ: CDNS) rose 12.4 percent to $41.30 in pre-market trading after the company posted upbeat Q1 results and issued a strong Q2 forecast. Aeglea BioTherapeutics, Inc. (NASDAQ: AGLE) rose 10.8 percent to $8.75 in pre-market trading. Mitel Networks Corporation (NASDAQ: MITL) rose 8.8 percent to $11.05 in pre-market trading after the company agreed to be acquired by affiliates of Searchlight Capital Partners for $2.0 billion. Galectin Therapeutics, Inc. (NASDAQ: GALT) rose 7.3 percent to $3.70 in pre-market trading. Riot Blockchain, Inc. (NASDAQ: RIOT) shares rose 6.9 percent to $7.00 in pre-market trading after declining 1.50 percent on Monday. Hallmark Financial Services, Inc. (NASDAQ: HALL) rose 6.5 percent to $10.68 in pre-market trading. Boot Barn Holdings, Inc. (NYSE: BOOT) rose 5.2 percent to $20.40 in pre-market trading after gaining 4.53 percent on Monday. New Oriental Education & Technology Group Inc. (NYSE: EDU) rose 5 percent to $91.16 in pre-market trading after reporting Q3 results. Shire plc (NASDAQ: SHPG) rose 5 percent to $167.98 in pre-market trading after Bloomberg reported that Takeda is nearing a preliminary agreement to acquire Shire after sweetened bid. Outfront Media Inc. (NYSE: OUT) shares rose 5 percent to $19.00 in pre-market trading. Geron Corporation (NASDAQ: GERN) rose 4.3 percent to $4.18 in pre-market trading after gaining 5.80 percent on Monday. SAP SE (NYSE: SAP) rose 3.7 percent to $109.80 in pre-market trading after the company posted strong quarterly results and raised its outlook for the year. Golden Ocean Group Limited (NASDAQ: GOGL) shares rose 3.7 percent to $8.70 in pre-market trading after gaining 1.45 percent on Monday. Deutsche Bank Aktiengesellschaft (NYSE: D
  • [By Motley Fool Staff]

    Cadence Design Systems (NASDAQ:CDNS) Q1 2018 Earnings Conference CallApril 23, 2018 5:00 p.m. ET

    Contents: Prepared Remarks Questions and Answers Call Participants Prepared Remarks:

    Operator

  • [By Timothy Green]

    Shares of Cadence Design Systems (NASDAQ:CDNS) jumped on Tuesday after the provider of design solutions for integrated circuits and electronic devices reported its first-quarter results. The company beat analyst estimates for both revenue and earnings, and it provided guidance that came in above analyst expectations. As of 1 p.m. EDT, the stock was up about 9.5%.

Hot Gold Stocks To Buy For 2019: CatchMark Timber Trust, Inc.(CTT)

Advisors' Opinion:
  • [By Ethan Ryder]

    Get a free copy of the Zacks research report on CatchMark Timber Trust (CTT)

    For more information about research offerings from Zacks Investment Research, visit Zacks.com

  • [By Max Byerly]

    Matarin Capital Management LLC acquired a new stake in shares of CatchMark Timber Trust (NYSE:CTT) in the 1st quarter, HoldingsChannel reports. The fund acquired 241,339 shares of the financial services provider’s stock, valued at approximately $3,009,000.

Hot Gold Stocks To Buy For 2019: Sempra Energy(SRE)

Advisors' Opinion:
  • [By Logan Wallace]

    Sempra Energy (NYSE: SRE) and Vectren (NYSE:VVC) are both utilities companies, but which is the superior investment? We will compare the two companies based on the strength of their profitability, dividends, risk, institutional ownership, valuation, analyst recommendations and earnings.

  • [By Tyler Crowe]

    Sempra Energy's (NYSE:SRE) acquisition of Oncor was a bit of a coup on Wall Street, as it was able to outbid Berkshire Hathaway for the Texas utility. The victory didn't come cheap, though, as Sempra had to cough up $9.5 billion and take on quite a bit of debt in the process of completing the deal. Even though the company sees immense potential in the purchase and the growth opportunities that come with it, shares of Sempra have been mostly flat for the past year.

  • [By Logan Wallace]

    Teacher Retirement System of Texas lowered its position in shares of Sempra Energy (NYSE:SRE) by 19.2% in the first quarter, HoldingsChannel.com reports. The fund owned 52,783 shares of the utilities provider’s stock after selling 12,538 shares during the quarter. Teacher Retirement System of Texas’ holdings in Sempra Energy were worth $5,871,000 as of its most recent filing with the SEC.

  • [By Lisa Levin] Companies Reporting Before The Bell Tyson Foods, Inc. (NYSE: TSN) is projected to report quarterly earnings at $1.32 per share on revenue of $9.89 billion. Sysco Corporation (NYSE: SYY) is estimated to report quarterly earnings at $0.64 per share on revenue of $14.34 billion. Louisiana-Pacific Corporation (NYSE: LPX) is expected to report quarterly earnings at $0.67 per share on revenue of $692.63 million. Cognizant Technology Solutions Corporation (NASDAQ: CTSH) is estimated to report quarterly earnings at $1.06 per share on revenue of 3.90 billion. Manchester United plc (NYSE: MANU) is estimated to report quarterly loss at $1.35 per share on revenue of $193.67 million. Sempra Energy (NYSE: SRE) is expected to report quarterly earnings at $1.66 per share on revenue of $3.24 billion. Willis Towers Watson Public Limited Company (NYSE: WLTW) is projected to report quarterly earnings at $3.01 per share on revenue of $2.23 billion. Green Plains Inc. (NASDAQ: GPRE) is estimated to report quarterly loss at $0.28 per share on revenue of $922.42 million. TravelCenters of America LLC (NASDAQ: TA) is projected to report quarterly loss at $0.16 per share on revenue of $1.59 billion. Gannett Co., Inc. (NYSE: GCI) is expected to report quarterly earnings at $0.03 per share on revenue of $723.93 million. Welbilt, Inc. (NYSE: WBT) is estimated to report quarterly earnings at $0.11 per share on revenue of $329.71 million. Horizon Pharma Public Limited Company (NASDAQ: HZNP) is projected to report quarterly earnings at $0.07 per share on revenue of $234.17 million.

     

Hot Gold Stocks To Buy For 2019: Invesco Municipal Opportunity Trust(VMO)

Advisors' Opinion:
  • [By Logan Wallace]

    Invesco Van Kampen Municpl Opprtnty Trst (NYSE:VMO) declared a monthly dividend on Tuesday, April 3rd, Wall Street Journal reports. Shareholders of record on Tuesday, April 17th will be paid a dividend of 0.0554 per share by the investment management company on Monday, April 30th. This represents a $0.66 dividend on an annualized basis and a dividend yield of 5.66%. The ex-dividend date of this dividend is Monday, April 16th.

Friday, May 25, 2018

Kura Oncology Sees Unusually Large Options Volume (KURA)

Kura Oncology (NASDAQ:KURA) was the target of unusually large options trading on Thursday. Stock investors bought 699 put options on the company. This represents an increase of 694% compared to the typical daily volume of 88 put options.

Institutional investors and hedge funds have recently modified their holdings of the business. MetLife Investment Advisors LLC bought a new stake in shares of Kura Oncology in the fourth quarter valued at $155,000. Barclays PLC raised its stake in shares of Kura Oncology by 67.0% in the first quarter. Barclays PLC now owns 8,977 shares of the company’s stock valued at $168,000 after buying an additional 3,600 shares during the period. American International Group Inc. raised its stake in shares of Kura Oncology by 42.0% in the fourth quarter. American International Group Inc. now owns 13,574 shares of the company’s stock valued at $208,000 after buying an additional 4,012 shares during the period. DekaBank Deutsche Girozentrale bought a new stake in shares of Kura Oncology in the first quarter valued at $226,000. Finally, Element Capital Management LLC bought a new stake in shares of Kura Oncology in the first quarter valued at $238,000. Hedge funds and other institutional investors own 70.24% of the company’s stock.

Get Kura Oncology alerts:

Shares of KURA opened at $17.20 on Friday. The firm has a market capitalization of $583.69 million, a price-to-earnings ratio of -11.32 and a beta of 4.28. The company has a debt-to-equity ratio of 0.04, a quick ratio of 12.37 and a current ratio of 12.37. Kura Oncology has a 1 year low of $5.90 and a 1 year high of $24.02.

Kura Oncology (NASDAQ:KURA) last issued its earnings results on Tuesday, May 8th. The company reported ($0.46) earnings per share (EPS) for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.35) by ($0.11). research analysts anticipate that Kura Oncology will post -1.75 earnings per share for the current fiscal year.

A number of analysts recently commented on KURA shares. Zacks Investment Research upgraded Kura Oncology from a “hold” rating to a “buy” rating and set a $22.00 price target on the stock in a report on Wednesday, March 21st. Cann reiterated a “buy” rating and set a $27.00 price target on shares of Kura Oncology in a report on Tuesday, April 17th. BidaskClub lowered Kura Oncology from a “strong-buy” rating to a “buy” rating in a report on Friday, March 16th. ValuEngine upgraded Kura Oncology from a “sell” rating to a “hold” rating in a report on Monday, April 2nd. Finally, Citigroup set a $28.00 price target on Kura Oncology and gave the stock a “buy” rating in a report on Friday, February 16th. One equities research analyst has rated the stock with a sell rating, two have assigned a hold rating and six have given a buy rating to the company. Kura Oncology presently has an average rating of “Buy” and a consensus target price of $22.00.

Kura Oncology Company Profile

Kura Oncology, Inc, a clinical-stage biopharmaceutical company, develops medicines for the treatment of cancers. Its pipeline consists of small molecule product candidates that target cancer. The company's lead product candidate is Tipifarnib, an oral farnesyl transferase inhibitor that is in Phase II clinical trials for the treatment of solid tumors, peripheral T-cell lymphomas, myelodysplastic syndromes, acute myeloid leukemia, and chronic myelomonocytic leukemia.

Thursday, May 24, 2018

A Conversation On Energy XXI Gulf Coast

By William T. Koldus and Darren McCammon

A Conversation Regarding Energy XXI Gulf Coast (EGC)

The following is a discussion regarding Energy XXI Gulf Coast between Darren McCammon of Cash Flow Kingdom and William Koldus of The Contrarian. We thought it might be useful to show readers the kind of constructive back and forth conversions that sometimes occur behind the paywall. The actual email conversation has been mildly edited to enhance readership for the publication of this article.

William's First Email (May 11th, 2018):

Hi Darren,

Recently, I published a Seeking Alpha public article, titled "Energy XXI Gulf Coast - Extraordinary Return Potential."

Previously, I had covered this in The Contrarian, my premium research service on Seeking Alpha.

In the commentary section of the article, several readers mentioned that you had also covered Energy Gulf Coast for your premium research service, Cash Flow Kingdom. As a previous fan of your work on Archrock (AROC), this intrigued me. I have a few questions.

First, what sparked your interest in Energy Gulf Coast?

Second, what was management of EGC thinking with their ARO transaction?

As CDM Capital noted in the commentary section (of the public article linked above), they moved the annual meeting, so they thought the move would be well received, but it seems overly complicated, and has left investors scratching their heads trying to figure it out. What is your brief take on this recent development?

Darren��s Initial Response:

Hi William,

I read your article, it was very well done. Yes, we've been following Energy XXI Gulf Coast off and on at Cash Flow Kingdom. Sorry this is going to be a bit long and convoluted answer. I'll try to minimize what I can.

I had an investment in CorEnergy (CORR) a while back when it was trading in the low teens. It had done a deal with Energy XXI (symbol EXXI at the time) to buy its pipeline and then lease it back to them. As part of due diligence on the CORR investment, I needed to decide if CORR was going to get paid (answer yes, by whomever owned those wells, EXXI or not), and ultimately, I learned more about Energy XXI.

When EXXI went bankrupt, another member of Seeking Alpha indicated they thought the unsecured EPL 8.25% notes had a very strong negotiation position in the bankruptcy, effectively a decent claim to first position on the EPL properties. Doing my own further research on this suggestion, I concluded that this appeared to be correct (though of course you never know what will happen in court) and the EPL notes were going to have their own lawyer (very important in a bankruptcy) ultimately buying some of those EPL notes at 5垄 on the dollar. We got one more interest payment as the company needed to buy a little more time, bringing the net cost down to 3垄.

Fast forward to near the end of the bankruptcy and the notes are now trading at 18 cents on the dollar (6x). Ultimately those translated into shares plus warrants, and I sold the shares at prices that were 6x - 3x gains, keeping the warrants (which I still own). Other much larger bondholders however couldn't sell without affecting price drastically, a disadvantage for them.

Since then, coverage of EXXI wasn't formal on my part, but a number of members of Cash Flow Kingdom kept up with it, even occasionally buying or selling. The underlying value in the PV10 reserves was there, especially in the (Proven and Possible assets) 2P, but there was (and still is) a whole lot of turmoil and uncertainty between here and there. In particular two CFK members tracked Franklin Resources and other major bankruptcy former bondholders unloading of their shares, trying to figure when would be the best time to get back in. When they indicated in chat, "I think Franklin is done or at least pretty darn close to it" backing it up with data, links and statistics, they pretty much nailed it on the head. Energy XXI Gulf Coast, now symbol EGC, was trading for less than $4 a share while simultaneously having an updated reputable third party 2P valuation a little over $30. I and others on Cash Flow Kingdom started to add. My current average price this time around being $5.30 with an allocation equal to 7.5% of my portfolio.

We know management already was working on this transaction a quarter ago when they hinted about pursuing a deal that involved selling non-core assets and, in the process, getting rid of a lot of ARO obligations. So, you have to put it in context, at the time WTI was trading around $60, and we had no idea whether it would decline back into the $50s (still don't by the way). Management's main problem is a lack of production due to almost no drilling since 2014. Get the production up, and costs fall significantly on a per barrel basis; fixed costs get spread over a larger base (in particular ARO gets better as it not only spreads but likely also gets further delayed), margins and cash flow goes way up, which in turn funds drilling, which increases production..... It��s a virtuous cycle, given the right price, but it has a chicken and egg problem. How do you get it started when you don't have the cash available to do the drilling you need and banks won't lend it to you in part because the Proven (1P) assets they are willing to lend on are so low (due to a lack of drilling)? This deal effectively solves that main problem by both removing a sizeable chunk of the ARO cost issues and priming the lending pump. To be clear, if we were still in the high $50s, low $60s on oil price, I'd think this a great deal.

Thoughts on the complex ARO deal and management moving the annual investor meeting time slot until after this call:

My initial read on the deal is it reduces the upside while also de-risking the downside significantly. Here's my estimate of strip PV-10 before and after the deal:

It is obviously a complex deal, but what you have basically done is traded upside, 2P goes from $30 to $24 per share, in return for de-risking the opportunity. A lot of ARO gets eliminated in return for shares (note both are already factored in to the PV-10 above), and in doing so likely allows them to arrange ongoing financing into 2019. This was clearly a good deal with prices around $60, but questionable with prices over $70 simply because I THINK there is now a better option.

My calculations (again done in conjunction with another CFK member) indicate prices received of $67 or better, combined with existing hedges and cash, should be enough to fund the drilling program. If correct, then they could instead choose to hedge all the existing production possible at LLS $67+ (LLS is the closest to what they actually get for their oil). Currently, factoring in heavy backwardation, that means they could hedge all production out to April 2019. As oil prices continue to rise, or we get closer to that date causing the backwardation to be less of a factor, we could then hopefully add hedges for May 2019, June, July, etc. While this limits our near-term upside, and still carries late 2019 funding risk, it also does not require any dilution.

That being said, my calculations could be wrong, and the existing deal is complex. I have some calls in trying to set up a discussion to better understand the deal, and hope to hear back with a time.

Side note: You didn't ask but I thought I'd point out from an operational point of view the last drill, West Delta 31 High Tide, is doing well. It came in 12% under planned cost and is now running at over planned production; 1,019 bo/d + 1.935 Mcf/d as of the 4/2/2018 well test, with the oil looking like it is continuing to ramp as the initial gas volume declines.

What do you think William? Is the ARO deal a good one? Do we really have the potential to not approve it down the road and if so what optionality does that imply? What about EGC as general investment either with or without the deal?

William:

Darren,

Thank you for the terrific, detailed response, including the closing comment about drilling results, touching on production, which is perhaps the key point going forward, IMO, for us EGC shareholders.

Elaborating on this further, if EGC could waive a "magic wand" and increase production today, it would be a "home-run" type of investment overnight. What the market is questioning, from my perspective, is their ability to raise financing to fund an enhanced drilling program, and/or their patience to wait for higher oil prices to kick in, to fund the accelerated drilling program, which is going to take time with their current hedges, and their declines in production over the past year.

Specific to the proposed ARO deal, I have a mixed opinion. On one hand, I can understand that it was negotiated during a time of lower oil prices. Thus, I am in agreement with you, that if oil prices were in the $50s, or even low $60s, I would applaud the deal, for the reasons you mentioned, including cleaning up the nearest-term AROs, and priming the runway for funding for drilling, which is desperately needed to increase production. On the other hand, oil prices are improving by the day, with signs of upward movement in longer-term prices. Building on this narrative, backwardation has actually narrowed over the past week, even with increasing prices at the front end, and the belly of the oil futures prices curve is starting to widen, which should be very bullish for EGC, and other downtrodden E&P producers, who have been waiting for higher future prices.

(Source: Art Berman)

All things being equal, if I owned the entire firm, I would rather let the undervalued asset appreciate, hedge where applicable to fund drilling in stages, and accelerate drilling if the futures curve cooperates. This scenario provides the most upside potential, however, it carries the highest risk. Thus, I think management has taken a middle of the road approach, de-risking, while securing funding for drilling.

You also asked, "do we really have the potential to not approve it down the road and if so what optionality does that imply?"

From my past experience, I have to think that EGC shopped the deal around to Oaktree (OAK), and others, and initially these firms passed on committing capital, thus leading us to the arms of ONR & Tom Clarke. However, now, with the recent movement in oil prices, perhaps Oaktree comes back to the table, not wanting to be diluted and superseded by another large shareholder, who is looking to capitalize on the opportunity. This last point is entirely speculation as I do not have direct knowledge of discussion. Having said this, the recent increase in oil prices, particularly if the oil futures curve continues its shift higher, is going to potentially throw a monkey wrench in this deal. What I mean is that normally I think this deal would go through nine times out of 10, or even a higher percentage, but now, I'm now so sure, and this uncertainty is going to cap EGC's share price in a sense, however, it also provides some upside optionality if a better deal comes along from another interested party.

EGC reminds me of a different firm in a different industry, and that firm is Genworth Financial ( GNW) which has an open deal right now to be acquired by China Oceanwide for $5.43 in cash (GNW shares closed today at $3.17). I followed GNW for a long time, personally buying shares in late 2008 and early 2009 for below $1 per share, and then selling these shares for 7x gains in 2009, not capturing all of the upside, but doing pretty well. I continued following this firm, and we bought shares in The Contrarian's Best Ideas Model Porfolio on 2/9/2016 for $1.75 per share, and then selling them on 6/28/2017 for $3.72 per share, for a gain of 113%. Today, there could be another opportunity, as the underlying business has improved, IMO, and shares are still trading well below the cash buyout offer of $5.43. Full disclosure, we own no position today.

(Source: WTK, StockCharts)

You may ask, why am I comparing GNW to EGC?

Well, the answer is, that the energy sector went through a horrific bear market, which, somewhat unbelievably, just ended for many energy equities, even though oil has been rising for over two years now. This bear market in energy equities, which occurred in stages from 2014-2018, depending on the particular energy equity, was every bit as brutal as the 2007-2009 declines in the broader stock market. (Building on this narrative, the decimation in the energy sector from 2014-2018 was very reminiscent of the decimation in financial equities from 2007-2009.)

For my members, I have used another analogy of homebuilders, which bottomed in 2009, but then made a secondary bottom in 2011. Long story short, the energy equity bear market has been brutal, and the resulting opportunity, if oil prices, natural gas liquids prices, and natural gas prices continue to cooperate, will be every bit as big for the surviving energy equities as it was for the beaten down equities like GNW in 2008/2009. Continuing the analogy, EGC has a tremendous amount of share price appreciation potential, almost a kinetic energy right now, yet in the long run, it could have similar path to GNW, so the initial surge higher could mark the recovery highs for a long time.

Looking back, I sold my initial GNW shares too early, even though I had tremendous gains. After that, GNW became a trading stock, which is what almost every stock is, IMO. On this note, the real long-term wealth is in buy-and-hold investments, but I think in the energy sector, it is very difficult to find these long-term investments, so really, these stocks are swing trades, not buy-and-hold forever equities. Specific to EGC I think that is going to be the challenge for EGC shareholders, in the months ahead, again assuming energy prices cooperate, knowing when to sell, as I think at some point, we will either reach a short-term peak, or EGC will be sold to another entity.

That is speculation for the future.

For now, I have two more questions for you. First, the more I look at EGC's financials, and past financials, ARO is already accounted for in their EBITDA, so it should not be a double hit to their EV/EBITDA calculations. Do you agree on this point?

Second, would an ideal outcome, the key word being "ideal" for EGC shareholders, simply be a slow ramp up from cash flows from drilling, with some selected hedging, till they are eventually able to self fund? We know the ideal outcome is not going to happen, but what would you do if you owned the whole company? How would you maximize value? And wrapping this series of questions up, what is the most likely outcome, given everyone's incentives, in your opinion?

Darren:

Thanks for that backwardation graph, I was looking for a source for that literally an hour ago. The GNW analogy and discussion helped put things in perspective also. I would note a nice thing about backwardation is it tends to be correlated with low and declining storage as well as price increases. Thus, while the backwardation may very well be a reason why EGC hasn't hedged more than it has yet, it is all good so far.

Anyway, the curve still looks pretty steep to me. It may have flattened a bit, but it's not terribly noticeable yet. Not enough for me to conclude it is flattening. As for your other questions:

1.) First, the more I look at EGC's financials, and past financials, ARO is already accounted for in their EBITDA, so it should not be a double hit to their EV/EBITDA calculations. Do you agree on this point?

Yes, but I sometimes include ARO in EV anyway just to get rid of whole, "but ARO is debt" objection. If I'm going to add ARO into EV, I should then also be pulling the ARO cost out of EBITDA, EBITDAARO? :), but I must confess I've been too lazy to do that. Sometimes you do something incorrect just because it forestalls an objection and the result is going to lead to the same decision anyway. I used to use straight EV/EBITDA but got tired of the "you��re not including ARO!" back and forth.

2.) Second, would an ideal outcome, the key word being "ideal," for EGC shareholders, simply be a slow ramp up from cash flows from drilling, with some selected hedging, till they are eventually able to self-fund?

Yes, assuming oil prices continue to rise.

3.) We know the ideal outcome is not going to happen, but what would you do if you owned the whole company? How would you maximize value?

If I were CFO, I would recommend hedging the heck out of LLS at whatever price I'd calculated pays for drilling the moment a future reached that price (I and another member of CFK jointly calculated this was probably around $67 per barrel). While this doesn't necessarily maximize value, particularly if oil goes to $100 over the next year like I think it might, but I'd do it anyway because I think it has the best risk / reward tradeoff for me personally.

The reason I would do this is because I don't know oil is going to $100, I just think it is. What I do know is funding drilling is my main problem and a lot of issues, including ARO, ultimately get solved by increasing drilling. I also know my current given alternative to fund drilling is 35% dilution. 35% dilution is permanent and therefore does a lot more harm to long-term value than hedging a year and a half��s production at $67 does (currently LLS can be hedged at $67 through July 2019). People will complain about that too, but ultimately you are trying to bridge to the point where production pays for drilling plus a profit. Why create a long-term solution (35% hedging) to what at its nature is a bridging problem if you don't have to?

That being said, I have to caveat that just a few months ago I would have jumped all over this deal. So, my intention is not to be critical of management here. I just think the price of oil changed and now we have better options open to us which retain more upside. Honestly, even if the deal went through as is, I'd just shrug and adjust my thinking to 90% of the new 2P value, it��s still a really nice gain.

4.) And wrapping this series of questions up, what is the most likely outcome, given everyone's incentives, in your opinion?

I'm glad you asked this question. Bear with me as I digress a bit, but it��s very pertinent to my answer. I have a basic belief that people do what they think is best for themselves most of the time. You do it, I do it, management will do it; maybe Saints don't, but I don't expect management to achieve Sainthood nor that a Saint would make a very good CEO. Anyway, this is a fundamental belief which has stood me well in life and I believe so true, that I need to follow where it leads (even when it leads places I don't like or agree with). So, in this case you have to put yourself in the place of management. What are they likely to think is best for themselves?

Well if I were management I would absolutely want to increase share value, because I have shares and options which I want to increase the value of. Heck, I probably got involved in what I knew would be a difficult, frustrating, and time-consuming situation(s) in part due to the potential of this carrot. However, at the same time, I as management have not just this carrot but a little thing called my paycheck to consider, and I feel like I've already put a thousand hours into the existing deal. So, I'd kind of like to keep my job and salary and maybe play with the kids every once in a while, too. These alternative incentives encourage me to take a satisfactory deal even if it is only "good" for the share price instead of optimal (hint management will frequently use the term "stakeholder" whenever they are about to do something that isn't necessarily in shareholders�� best interests).

That being said, I expect Oaktree and other similar major shareholders will hire ISS or Glass Lewis to make a recommendation. If they make us privy to it that will also be an important recommendation to consider. Ultimately, Oaktree is going to probably have the biggest say. That may mean pushing back, it may mean taking the deal and moving forward. Again, realize the person making that decision at Oaktree is probably an employee with a bonus who recommended the purchase of EGC in the first place, not necessarily a direct owner of the shares. Additionally, Oaktree owns shares because it bought the bonds in bankruptcy and is probably looking at something like a $4.50 average cost. So, given there's usually time pressures to cash out and move on, $18 in the next 12 months vs. $30 in 24 months, might look a bit different for them than it does for you and I. Overall, I take comfort from the fact that Oaktree and the like are going to be both knowledgeable and pretty well aligned with my interests. Ultimately, knowing what I know now, and not having heard back from my sources yet, when it comes time to vote I will probably:

Vote no at $75 oil and above Vote yes at $60 oil and below In between it could go either way

I'd also add I'm not sure that's not exactly what management might not prefer we do (though they can't necessarily say it publicly). If this really is an option with no breakup fee, it��s a pretty sweet deal. Additionally, I'd like to point out what we are probably really talking about here is whether EGC is ultimately targeted at 3x or 5x current price per share (given $70 oil). Frankly, I'd be happy with either.

I think this has been a fruitful discussion. Thanks for reaching out and responding. We can still carry on, but I think it might be useful to post this for my Cash Flow Kingdom members. Would you be OK with it if I started doing that?

William:

Darren,

Yes, thank you for taking the time for the exchange.

Go ahead and post for CFK. I will do the same, either tomorrow or Wednesday, depending on work schedule. Maybe a week from now, we can clean this up, and publish publicly, with both of us listed as authors. Let me know if you want to go that direction? I think there is a genuine opportunity here to have a nice capital gain.

Once we find out which way Oaktree is leaning, that will provide more context.

Darren's Follow-Up Note

William,

I heard back from my sources. Apparently, investment banks will only allow hedging of 75% of known production with that being reduced to 55% for Gulf offshore producers during the July �� October hurricane season. Unfortunately, this ends up changing the picture quite a bit. It��s very limiting given that the current production already is partially hedged and abnormally low due to lack of prior year drilling. Again, the chicken and egg problem. Can��t drill because we don��t have the funding, can��t fund because we don��t have the production from drilling. Thus, my original suggestion to hedge 100% of production at $67+ in order to bridge the cash need isn��t going to work.

Additionally, management didn��t talk about it in the conference call, but I��ve now had a chance to look at the cash flow statement. I see they have a little over three quarters of burn left. Thus, were the next hole drilled to be dry, we would suddenly be in a world of hurt. It��s still the same bridging problem, but a riskier one than I first imagined. I��ll probably vote however ISS recommends and/or Oaktree votes, but I��ll no longer be surprised if that recommendation is to take some version of the deal. We are probably talking more than a 3 bagger from here with the deal maybe taking the risk for a potential 4 bagger instead just isn��t worth it?

William��s Closing Note:

Energy XXI Gulf Coast has been on my radar for over a year, ever since they exited their prior restructuring. Darren has been covering the company through the restructuring process. As the price of oil has continued to rise, and Energy XXI Gulf Coast shares have continued to drop, it has become a interesting, potentially compelling opportunity.

(Source: WTK, StockCharts)

We initially took a position in EGC shares in The Contrarian��s Best Ideas Model Portfolio (a Portfolio that returned 126.4% in 2016, and lost -0.9% in 2017) early in the month of May, 2018, and our fair value target for the equity of Energy XXI Gulf Coast, given prevailing oil prices, is much higher than EGC��s share price currently.

After delving deeper and deeper into EGC over the past month, including a weekend where I looked at all the financial filings over the past five years, I believe that Energy XXI Gulf Coast has gotten trapped in a downward spiral, swamped by the asset retirement obligations that get more onerous with lower production. The other side of the coin is that this downward death spiral can be turned into a virtuous cycle with higher production and higher oil prices.

Tracking back to the asset retirement obligations, which is the key overhang holding back EGC shares today, in my opinion, the PV-10 values, which Darren showed in the article above, already account for the ARO, and I think EGC shares get unfairly dinged by the analyst community since ARO expenses are calculated as part of the EV/EBITDA calculations, yet almost all of these analysts then lump in ARO as additional long-term debt, which is a double penalty.

Bottom line, with oil prices significantly above the last PV-10 valuations (Darren��s table earlier in the article) there is significant appreciation potential if EGC can execute operationally.

Darren and I hope that this has been a beneficial exchange for investors in Energy XXI Gulf Coast, and we encourage any questions, comments, or feedback to be posted in the discussion thread below.

If you liked this article, please be sure to ��Follow�� Darren, and myself, for future public research. Thank you for your time, and readership.

Darren��s marketing: FREE two-week trial to Cash Flow Kingdom PLUS $100 off the first years annual membership!

For the first time ever, we are offering the public a FREE two-week trial to check out Cash Flow Kingdom, and $100 of the first year of your annual membership when you decide to stick around after that free trial period. We've never made offer to the public before and may never do so again. So, if you would like to find out more about the equities listed above, or what other investments are on the Income List, now is the time. Ask yourself, what do you have to lose?

William��s marketing

William's marketing: Rare two-week free trial currently open to The Contrarian

Recently we published a 55-page deep dive research article on one of our most compelling long ideas, and to celebrate, we are extending the window for our two-week free trial to The Contrarian. With a two-and-a-half year track record of Model Portfolio��s that have generally significantly outperformed the markets, and their targeted benchmarks, The Contrarian offers a rare window into what we think are some of the best value investments in the stock market today.

Disclosure: I am/we are long EGC, AROC.

I wrote this article myself, and it expresses my own opinions. I am not receiving compensation for it (other than from Seeking Alpha). I have no business relationship with any company whose stock is mentioned in this article.

Additional disclosure: Additional disclosure: This article discusses a speculative investment. I do not know your goals, risk tolerance, or particular situation; therefore, I cannot recommend any investment to you. Please do your own additional due diligence. Additional disclosure: Every investor's situation is different. Positions can change at any time without warning. Please do your own due diligence and consult with your financial advisor, if you have one, before making any investment decisions. The author is not acting in an investment adviser capacity. The author's opinions expressed herein address only select aspects of potential investment in securities of the companies mentioned and cannot be a substitute for comprehensive investment analysis. The author recommends that potential and existing investors conduct thorough investment research of their own, including detailed review of the companies' SEC filings. Any opinions or estimates constitute the author's best judgment as of the date of publication, and are subject to change without notice.

Tuesday, May 22, 2018

KBC Group NV Purchases 15,628 Shares of Medtronic PLC (MDT)

KBC Group NV boosted its position in Medtronic PLC (NYSE:MDT) by 2.4% in the first quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The institutional investor owned 655,442 shares of the medical technology company’s stock after purchasing an additional 15,628 shares during the period. KBC Group NV’s holdings in Medtronic were worth $52,580,000 at the end of the most recent quarter.

Other institutional investors and hedge funds have also recently modified their holdings of the company. We Are One Seven LLC acquired a new stake in shares of Medtronic in the fourth quarter valued at about $104,000. BB&T Investment Services Inc. increased its stake in shares of Medtronic by 147.6% in the fourth quarter. BB&T Investment Services Inc. now owns 1,518 shares of the medical technology company’s stock valued at $126,000 after buying an additional 905 shares during the period. Barrett Asset Management LLC increased its stake in shares of Medtronic by 856.0% in the fourth quarter. Barrett Asset Management LLC now owns 1,826 shares of the medical technology company’s stock valued at $147,000 after buying an additional 1,635 shares during the period. Proficio Capital Partners LLC increased its stake in shares of Medtronic by 51.2% in the fourth quarter. Proficio Capital Partners LLC now owns 2,201 shares of the medical technology company’s stock valued at $178,000 after buying an additional 745 shares during the period. Finally, Bedel Financial Consulting Inc. acquired a new stake in shares of Medtronic in the first quarter valued at about $193,000. 80.37% of the stock is owned by institutional investors and hedge funds.

Get Medtronic alerts:

MDT has been the subject of several recent research reports. Citigroup reissued a “buy” rating and issued a $93.00 price target (down previously from $100.00) on shares of Medtronic in a research note on Thursday, February 22nd. Royal Bank of Canada reaffirmed an “outperform” rating and set a $92.00 target price on shares of Medtronic in a research note on Wednesday, February 14th. Oppenheimer reaffirmed a “buy” rating on shares of Medtronic in a research note on Tuesday, March 20th. Piper Jaffray Companies started coverage on Medtronic in a research note on Friday, April 27th. They set an “overweight” rating and a $90.00 target price for the company. Finally, Morgan Stanley decreased their target price on Medtronic from $95.00 to $90.00 and set an “equal weight” rating for the company in a research note on Thursday, March 29th. One research analyst has rated the stock with a sell rating, six have issued a hold rating and seventeen have issued a buy rating to the stock. The company currently has a consensus rating of “Buy” and a consensus target price of $91.39.

Shares of Medtronic opened at $84.64 on Monday, MarketBeat reports. The company has a market capitalization of $114.72 billion, a price-to-earnings ratio of 18.05, a PEG ratio of 2.32 and a beta of 0.94. The company has a debt-to-equity ratio of 0.51, a quick ratio of 2.09 and a current ratio of 2.43. Medtronic PLC has a 52-week low of $76.41 and a 52-week high of $89.72.

Medtronic (NYSE:MDT) last announced its quarterly earnings results on Tuesday, February 20th. The medical technology company reported $1.17 earnings per share (EPS) for the quarter, topping the consensus estimate of $1.16 by $0.01. The business had revenue of $7.37 billion for the quarter, compared to analyst estimates of $7.20 billion. Medtronic had a return on equity of 12.65% and a net margin of 9.44%. The company’s quarterly revenue was up 1.2% on a year-over-year basis. During the same quarter in the prior year, the company earned $1.12 earnings per share. equities research analysts anticipate that Medtronic PLC will post 4.74 earnings per share for the current year.

In other Medtronic news, Director James T. Lenehan sold 1,306 shares of the stock in a transaction that occurred on Tuesday, March 13th. The stock was sold at an average price of $83.56, for a total value of $109,129.36. The sale was disclosed in a document filed with the SEC, which is available at this hyperlink. Also, SVP Carol A. Surface sold 24,479 shares of the stock in a transaction that occurred on Monday, March 5th. The stock was sold at an average price of $78.18, for a total value of $1,913,768.22. The disclosure for this sale can be found here. 0.31% of the stock is currently owned by corporate insiders.

Medtronic Company Profile

Medtronic plc manufactures and sells device-based medical therapies to hospitals, physicians, clinicians, and patients worldwide. The company's Cardiac and Vascular Group segment offers implantable cardiac pacemakers, cardioverter defibrillators, and cardiac resynchronization therapy devices; diagnostics and monitoring devices; mechanical circulatory support, TYRX, and AF products; and remote monitoring and patient-centered software.

Institutional Ownership by Quarter for Medtronic (NYSE:MDT)

Sunday, May 20, 2018

Top Tech Stocks To Buy Right Now

tags:HGSH,OAS,ENSV,

Is Twitter Inc. (TWTR) doomed?

That would certainly seem to be the case, given its stock market performance over the last couple of years.

After reporting almost flat user growth for the last couple of quarters, the San Francisco-based company reported mixed earnings yesterday. It beat analyst expectations for revenue but fell short in user numbers and future guidance. (See also: Twitter Stock Punished Despite User Growth, EPS Beat.)

"If you've got a social media service that's just flat, then that's not great news," said Bob O'Donnell, analyst at Technanlysis Research, adding references to Facebook Inc. (FB) and Weibo, which have reported increase in user growth.

Top Tech Stocks To Buy Right Now: China HGS Real Estate, Inc.(HGSH)

Advisors' Opinion:
  • [By Money Morning Staff Reports]

    But before we show you our pick, here are the top 10 penny stocks to watch this week…

    Penny Stocks Current Share Price (as of Jan. 5) Jan. 2-5 Gain (as of Jan. 5) My Size Inc. (Nasdaq: MYSZ) $1.66 152.28% Cytori Therapeutics Inc. (Nasdaq: CYTX) $0.47 89.52% DelMar Pharmaceuticals Inc. (Nasdaq: DMPI) $1.675 58.02% CAS Medical Systems Inc. (Nasdaq: CASM) $1.09 55.71% China HGS Real Estate Inc. (Nasdaq: HGSH) $1.83 47.58% Aethlon Medical Inc. (Nasdaq: AEMD) $1.56 43.12% Midatech Pharma Plc. (Nasdaq: MTP) $1.23 43.01% Comstock Holding Cos. Inc. (Nasdaq: CHCI) $1.87 36.5% Cenveo Inc. (Nasdaq: CVO) $1.20 31.82% EV Energy Partners LP (Nasdaq: EVEP) $0.6844 31.62%


    FREE PROFIT ALERTS: Get real-time recommendations on the best penny stock opportunities the moment we release them. Just sign up here, it's completely free…

Top Tech Stocks To Buy Right Now: Oasis Petroleum Inc.(OAS)

Advisors' Opinion:
  • [By Lisa Levin]

    Check out these big penny stock gainers and losers

    Losers Akorn, Inc. (NASDAQ: AKRX) fell 32.7 percent to $13.25 in pre-market trading after Fresenius terminated its merger deal with Akorn. Chicago Bridge & Iron Company N.V. (NYSE: CBI) fell 15.7 percent to $12.30 in pre-market trading. Subsea 7 confirmed a $7.00 per share proposal to acquire Mcdermott, pending termination of merger agreement with CB&I. Myomo, Inc. (NYSE: MYO) fell 9 percent to $3.65 in pre-market trading after rising 11.39 percent on Friday. Hasbro, Inc. (NASDAQ: HAS) fell 8 percent to $88.36 in pre-market trading after the company reported weaker-than-expected results for its first quarter on Monday. SunPower Corporation (NASDAQ: SPWR) fell 7.1 percent to $9.00 in pre-market trading. Endeavour Silver Corp. (NYSE: EXK) shares fell 5.9 percent to $2.88 in pre-market trading after declining 3.16 percent on Friday. Mattel, Inc. (NASDAQ: MAT) shares fell 5.5 percent to $12.25 in pre-market trading. Valeritas Holdings, Inc. (NASDAQ: VLRX) shares fell 5.1 percent to $2.96 in pre-market trading after rising 76.27 percent on Friday. GlobalSCAPE, Inc. (NYSE: GSB) fell 5.1 percent to $3.57 in pre-market trading. Fresenius Medical Care AG & Co. KGaA (NYSE: FMS) shares fell 4.1 percent to $49.93 in pre-market trading. Oasis Petroleum Inc. (NYSE: OAS) fell 4.1 percent to $9.75 in pre-market trading. SunTrust Robinson Humphrey downgraded Oasis Petroleum from Hold to Sell
  • [By Lisa Levin]

     

    Companies Reporting After The Bell Hertz Global Holdings, Inc. (NYSE: HTZ) is projected to post quarterly loss at $1.31 per share on revenue of $1.97 billion. International Flavors & Fragrances Inc. (NYSE: IFF) is estimated to post quarterly earnings at $1.59 per share on revenue of $909.36 million. Zillow Group, Inc. (NASDAQ: ZG) is expected to post quarterly earnings at $0.06 per share on revenue of $294.79 million. General Cable Corporation (NYSE: BGC) is estimated to post quarterly earnings at $0.15 per share on revenue of $980.61 million. Central Garden & Pet Company (NASDAQ: CENT) is expected to post quarterly earnings at $0.84 per share on revenue of $598.45 million. Cabot Corporation (NYSE: CBT) is estimated to post quarterly earnings at $1 per share on revenue of $746.42 million. Fabrinet (NYSE: FN) is expected to post quarterly earnings at $0.71 per share on revenue of $319.71 million. National General Holdings Corp. (NASDAQ: NGHC) is projected to post quarterly earnings at $0.55 per share on revenue of $1.08 billion. The Navigators Group, Inc. (NASDAQ: NAVG) is estimated to post quarterly earnings at $0.75 per share on revenue of $320.92 million. Diplomat Pharmacy, Inc. (NYSE: DPLO) is expected to post quarterly earnings at $0.22 per share on revenue of $1.29 billion. Trex Company, Inc. (NYSE: TREX) is projected to post quarterly earnings at $1.19 per share on revenue of $172.22 million. AMC Entertainment Holdings, Inc. (NYSE: AMC) is expected to post quarterly earnings at $0.09 per share on revenue of $1.35 billion. Envision Healthcare Corporation (NYSE: EVHC) is projected to post quarterly earnings at $0.64 per share on revenue of $2.02 billion. Regal Beloit Corporation (NYSE: RBC) is estimated to post quarterly earnings at $1.23 per share on revenue of $869.64 million. Amedisys, Inc. (NASDAQ: AMED) is projected to post quarterly earnings at $0.67 per share on revenue of $39
  • [By Benzinga News Desk]

    The curtain could come down any day on MoviePass’ bumpy run as an independent company: Link

    ECONOMIC DATA Chicago Fed national activity index +0.10 vs +0.27 expected The Composite Purchasing Managers' Index for April will be released at 9:45 a.m. ET. Existing home sales report for March is schedule for release at 10:00 a.m. ET. The Treasury is set to auction 3-and 6-month bills at 11:30 a.m. ET. ANALYST RATINGS Deutsche Bank upgraded Michael Kors (NYSE: KORS) from Hold to Buy RBC downgraded Paylocity (NASDAQ: PCTY) from Outperform to Sector Perform Suntrust downgraded Oasis Petroleum (NYSE: OAS) from Hold to Sell

    This is a tool used by the Benzinga News Desk each trading day — it's a look at everything happening in the market, in five minutes. To get the full version of this note every morning, click here.

  • [By Max Byerly]

    Oasis Petroleum (NYSE:OAS) has been given a $10.00 price target by equities researchers at Stifel Nicolaus in a report issued on Tuesday. The brokerage presently has a “hold” rating on the energy producer’s stock. Stifel Nicolaus’ target price points to a potential downside of 11.82% from the stock’s current price.

  • [By Garrett Baldwin]

    Oil prices are at levels we haven't seen in years. U.S. crude topped $70 for the first since 2014, as U.S. President Donald Trump appeared increasingly likely to pull out of the Iran nuclear deal and reinforce sanctions on Tehran. In addition, OPEC has announced plans to bolster prices and cap production. For oil investors, Money Morning�Global Energy Strategist Dr. Kent Moors says it's time to buckle up. According to Moors, revoking the Iran deal would cause "price chaos" around the globe. And that's right as driving season starts in the United States. Here's more on the coming chaos for oil. In deal news, Blackstone Group (NYSE: BX) announced it will purchase Gramercy Property Trust (NYSE: GPT) for $7.6 billion in cash. Grammercy manages commercial real estate. While this may seem like a boring deal, Blackstone is buying a business that churns out cold hard cash for its investors. We want to keep this deal on your radar, because there are many other deals like this coming down the pipeline. We're going to be discussing one of the best real estate opportunities available very soon – so keep an eye out for updates. Three Stocks to Watch Today: AMZN, AAPL, TSN, SBUX Shareholders of Amazon.com Inc. (Nasdaq: AMZN) cheered statements made by Warren Buffett over the weekend. The Oracle of Omaha said he messed up by not investing in Amazon and Alphabet Inc. (Nasdaq: GOOGL). "I made the wrong decisions on Google and Amazon," Buffett said on Saturday. "We've looked at it. I made the mistake in not being able to come to a conclusion where I really felt that at the present prices that the prospects were far better than the prices indicated." Buffett says he now has a "very, very, very high opinion" of Amazon CEO Jeff Bezos. The Oracle believes that Bezos has created something that is "close to a miracle." Apple Inc. (Nasdaq: AAPL) added another 0.6% Monday, to reach $185.00 per share – a new 52-week high. The uptick came after Warren Buffett announced

Top Tech Stocks To Buy Right Now: ENSERVCO Corporation(ENSV)

Advisors' Opinion:
  • [By Logan Wallace]

    Enservco (NYSEAMERICAN:ENSV) will be issuing its quarterly earnings data before the market opens on Wednesday, May 9th.

    Enservco (NYSEAMERICAN:ENSV) last issued its earnings results on Thursday, March 22nd. The oil and gas producer reported ($0.04) earnings per share for the quarter, missing the Zacks’ consensus estimate of ($0.01) by ($0.03). Enservco had a negative return on equity of 89.94% and a negative net margin of 43.71%. The business had revenue of $14.13 million during the quarter.